Floatz logo

Paliperidone Palmitate 3-Month Formulation

Schizophrenia Spectrum and Other Psychotic Disorders

Réseau de Santé Vitalité Health NetworkDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Schizophrenia Spectrum and Other Psychotic Disorders cohort.

Asset / SponsorPhaseRating
Risperdal
Réseau de Santé Vitalité Health Network
Phase 4BB
Metformin
The University of Hong Kong
Phase 2/3B
UMBELLATINE
The University of Hong Kong
Phase 2/3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Region Örebro County
Phase 2B
Olanzapine
University Hospital, Strasbourg, France
Phase 2CCC
ly03010
Luye Pharma Group Ltd.
Phase 1CC
PALIPERIDONE PALMITATE , (R)-
Réseau de Santé Vitalité Health Network
D

Same molecule, other indications

Paliperidone Palmitate 3-Month Formulation is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →